Not provided
Not provided
Not provided
Not provided
Not provided
PI decision
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The diagnosis of Growth Hormone deficiency in childhood requires the performance of an artificial pharmacological stimulation tests. There are number of substances that increase the secretion of growth hormone, among them Clonidine and Arginine. One of the possible side effects of both Clonidine and Arginine is a reduction in the blood pressure due to a decreased heart output and declined contraction of peripheral blood vessels. In cases where values of blood pressure at the end of the test are not recovered after two sessions of 15 minutes of physical activity, the patient is treated with I. V of 9%NORMAL SALINE (0. 20cc /Kg) administrated over 30-60 minutes.
The aim of the proposed study is to test whether administration of fluids during the combined Growth Hormone stimulation test Clonidine-Arginine will help in the recovery process from the test (blood pressure > 90/50 mmHg after performing physical activity defined as 15-minutes hike in two consecutive sessions). The study design will be randomized, controlled, 2 arms study.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intravenous fluid administration | Experimental | This arm will include 20 children who received Testoviron or Estrofem prior to the the stimulation test and 40 children who did not receive preparation prior to the stimulation test. Participants in this arm will be treated with I. V of 9%NORMAL SALINE (0. 20cc /Kg) administrated over 60 minutes. The fluids treatment will be initiated 90 minutes after the stimulation test will begin |
|
| Control Group | No Intervention | This arm will include 20 children who received Testoviron or Estrofem prior to the the stimulation test and 40 children who did not receive preparation prior to the stimulation test. Participants in this arm will not receive fluids intravenously during the stimulation test, unless it will be required due to safety reasons |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 9% Sodium Chloride (NaCl) IV | Procedure | 9% Sodiun Chloride (NaCl) ( 20cc/kg) adminstrated intravenously |
|
| Measure | Description | Time Frame |
|---|---|---|
| Average blood pressure | Average blood pressure ( 3 measurements in 5 minutes intervals) | Time 180 mnutes- at time of discharging the participant |
| Measure | Description | Time Frame |
|---|---|---|
| Average blood pressure | Average blood pressure ( 3 measurements in 5 minutes intervals) | Time 0- prior to initiating the Growth Hormone test |
| Average blood pressure | Average blood pressure ( 3 measurements in 5 minutes intervals) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Moshe Phillip, Prof | Schneider Children's Medical Center, Israel | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Schneider Children's Medical Center of Israel | Petah Tikva | 4920235 | Israel |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D004393 | Dwarfism, Pituitary |
| ID | Term |
|---|---|
| D004392 | Dwarfism |
| D001848 | Bone Diseases, Developmental |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D012965 | Sodium Chloride |
| ID | Term |
|---|---|
| D002712 | Chlorides |
| D006851 | Hydrochloric Acid |
| D017606 | Chlorine Compounds |
| D007287 | Inorganic Chemicals |
Not provided
Not provided
Randomized, 2 arms, controlled study
Not provided
Not provided
Not provided
Not provided
| Time 90 minutes after completing the Arginine adminstration |
| Average blood pressure | Average blood pressure ( 3 measurements in 5 minutes intervals) | Time 150 minutes after completing the Arginine adminstration |
| Time elapsed between completing the Growth Hormone test until participant is allowed to go home | Time 180 minutes-at time of discharging the participant (after measuring blood pressure > 50/90mm/Hg) |
| D001849 |
| Bone Diseases, Endocrine |
| D007018 | Hypopituitarism |
| D010900 | Pituitary Diseases |
| D007027 | Hypothalamic Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D004700 | Endocrine System Diseases |
| D017670 |
| Sodium Compounds |